研究等業績 - その他 - 羽渕 友則
-
Fujiyama N.
Clinical and Experimental Nephrology ( Clinical and Experimental Nephrology ) 27 ( 12 ) 1010 - 1020 2023年12月
-
Okamoto T.
Journal of Nephrology ( Journal of Nephrology ) 36 ( 9 ) 2613 - 2620 2023年12月
-
Fujiyama N.
Clinical and Experimental Nephrology ( Clinical and Experimental Nephrology ) 27 ( 12 ) 1021 - 1022 2023年12月
-
Sasagawa H.
Journal of Cancer Research and Clinical Oncology ( Journal of Cancer Research and Clinical Oncology ) 149 ( 16 ) 15091 - 15094 2023年11月
-
Horie S.
International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 28 ( 11 ) 1538 - 1544 2023年11月
-
Koguchi T.
Cancer Medicine ( Cancer Medicine ) 12 ( 22 ) 20677 - 20689 2023年11月
-
Tanaka R.
International Journal of Urology ( International Journal of Urology ) 30 ( 11 ) 969 - 976 2023年11月
-
Okubo K.
Case Reports in Oncology ( Case Reports in Oncology ) 16 ( 1 ) 621 - 627 2023年08月
-
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study
Shiota M.
Endocrine-Related Cancer ( Endocrine-Related Cancer ) 30 ( 7 ) 2023年07月
-
Kato R.
International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 28 ( 5 ) 726 - 727 2023年05月
-
BRAF V600E変異は副腎腫瘍からのコルチゾール産生を亢進する(BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma)
沼倉 一幸, 武藤 弓奈, 杉山 志子, 小林 瑞貴, 関根 悠哉, 嘉島 相輝, 山本 竜平, 奈良 健平, 黄 明国, 齋藤 満, 成田 伸太郎, 西本 紘嗣郎, 羽渕 友則
日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 ) 110回 AOP08 - 03 2023年04月
-
増刊号特集 泌尿器内視鏡最新手術 副腎・腎・後腹膜の手術 ロボット支援腹腔鏡下腎尿管全摘除術[右・左]
齋藤 満, 成田 伸太郎, 羽渕 友則
臨床泌尿器科 ( 株式会社医学書院 ) 77 ( 4 ) 67 - 71 2023年04月
-
Yanagisawa T.
Prostate ( Prostate ) 83 ( 6 ) 563 - 571 2023年
PURPOSE: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting. METHODS: The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), time to 2nd-line progression (PFS2), and 2nd- and 3rd-line PFS, were compared. We used one-to-two propensity score matching to minimize the confounders. The differential efficacy of 2nd-line therapy based on agents in each arm was evaluated using the unmatched cohort as an additional interest. RESULTS: After propensity score matching, 86 patients treated with DOC + ADT and 172 with ABI + ADT were available for analyses. The 3-year OS and CSS for DOC versus ABI were 76.2% versus 75.1% (p = 0.8) and 78.2% versus 78.6% (p = 1), respectively. There was no difference in the median PFS2 (49 vs. 43 months, p = 0.39), while the median time to CRPC in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). The median 2nd-line PFS (14 vs. 4 months, p < 0.001) and 3rd-line PFS (4 vs. 2 months, p = 0.012) were significantly better in the DOC group than in the ABI group. Among the unmatched cohort, after ABI for mHSPC, the median 2nd-line PFS did not differ between the patients treated with DOC and those treated with enzalutamide as 2nd-line therapy (both 3 months, p = 0.8). CONCLUSIONS: ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high-risk mHSPC. Compared to DOC, ABI resulted in longer time to CRPC but worse 2nd and 3rd-line PFS. Further studies are needed to clarify the optimal sequence of therapy in the upfront intensive treatment era.
-
Shiota M.
Cancer Science ( Cancer Science ) 114 ( 4 ) 1625 - 1634 2023年
Genetic variations represented by single-nucleotide polymorphisms (SNPs) could be helpful for choosing an effective treatment for patients with prostate cancer. This study investigated the prognostic and predictive values of SNPs associated with the prognoses of pharmacotherapy for prostate cancer through their pharmacological mechanisms. Patients treated with docetaxel or androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, for castration-resistant prostate cancer were included. The SNPs of interest were genotyped for target regions. The prognostic and predictive values of the SNPs for time to progression (TTP) were examined using the Cox hazard proportional model and interaction test, respectively. Rs1045642 in ABCB1, rs1047303 in HSD3B1, rs1856888 in HSD3B1, rs523349 in SRD5A2, and rs34550074 in SLCO2A1 were differentially associated with TTP between docetaxel chemotherapy and ARPI treatment. In addition to rs4775936 in CYP19A1, rs1128503 in ABCB1 and rs1077858 in SLCO2B1 might be differentially associated with TTP between abiraterone and enzalutamide treatments. Genetic predictive models using these SNPs showed a differential prognosis for treatments. This study identified SNPs that could predict progression as well as genetic models that could predict progression when patients were treated with docetaxel versus ARPI and abiraterone versus enzalutamide. The use of genetic predictive models is expected to be beneficial in selecting the appropriate treatment for the individual patient.
-
Morizane S.
International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 2023年
-
序文
羽渕 友則
Japanese Journal of Endourology and Robotics ( 一般社団法人 日本泌尿器内視鏡・ロボティクス学会 ) 36 ( 1 ) 79 - 79 2023年
<p> ロボット支援手術の含む『腹腔鏡・ロボット支援手術のポート位置について : エキスパートの考え方を聞く』の本特集を企画したら, 失礼ではあるが, 期待以上に面白く, 示唆に富む内容になった. 先ずは, 執筆していただいたエキスパートの先生がたに心から深謝したい.</p><p> さて, 開放手術においてもその切開の部位, 方向, 長さによってその手術の良否が大きく左右される. 例を挙げるまでもなく, IVC腫瘍塞栓を有する肝浸潤を伴う大きな腎癌の手術などでは術前のシミュレーションと患者の体型と腫瘍の進展度から入念に切開を決めることが最初のキーポイントである.</p><p> 開放手術以上にアクセスポイントが重要なのが, 腹腔鏡手術やロボット支援手術である. これらの手術は始めに設置された数本のポートを介して標的にアプローチする. ロボット支援手術では鉗子の先端の可動性は増したとは言え, 標的部位の近くまでは直線方向に限局される. したがって腹腔鏡でもロボット支援手術でもそのポート位置によってカメラや鉗子類が到達できる範囲や角度が制限され, 最初に決定されたポート位置で, その手術の難易度が大きく変わる. さらに理想のポート位置は, 腫瘍や標的臓器の位置やサイズ, 患者体型, 使用予定の機器や鉗子, 持針器 (左右のどちらの手で縫合するか) によって変化する. 個々の症例でどのように位置を変えていくかは術者のセンスが問われる.</p><p> フライトにおいて離陸と着陸が重要なポイントであるように, ポート位置とサイズの選定は今日のフライトを快適に安全にリードする為のキーポイントである. “ヘボ”なポート位置では, いくらエキスパートがリカバーしようとしても“骨折りの苦しい手術, 見苦しいriskyな手術”になってしまう.</p><p> 腹腔鏡手術, ロボット支援手術のエキスパートによる考え方, 戦略への思考が大いに参考になるこの特集号を腹腔鏡やロボット支援手術を執刀する方々に是非一読していただきたい.</p>
-
Habuchi T.
European Urology ( European Urology ) 84 ( 1 ) 141 - 142 2023年
-
Numakura K.
World Journal of Surgical Oncology ( World Journal of Surgical Oncology ) 20 ( 1 ) 202 - 202 2022年12月
INTRODUCTION: Warm ischemia time (WIT) is a primary concern for robot-assisted laparoscopic partial nephrectomy (RALPN) patients because longer WIT is significantly associated with postoperative deteriorating kidney function. Tumor complexity, determined by the RENAL nephrometry score (RENAL score), can help predict surgical outcomes, but it is unclear what RENAL score and clinical factors affect WIT. This study explored the clinical factors predicting long WIT in experienced surgeon to RALPN. MATERIALS AND METHODS: In our institute, 174 RALPNs were performed between November 2013 and February 2021, of which 114 were performed by a single surgeon and included in this study. Clinical staging and the total RENAL score were determined based on preoperative CT scans. The cases were divided into three groups based on experience: period 1: 1-38, period 2: 39-76, and period 3: 77-114. The clinical factors associated with longer WIT were analyzed per period. RESULTS: The overall median tumor diameter was 32 mm, and one patient had a positive surgical margin, but there were no cancer-related deaths. In total, there were 18 complications (15.8%). Periods 2 and 3 had larger tumor diameters (p < 0.01) and worse preoperative kidney function (p = 0.029) than period 1. A RENAL L-component score of 3 was associated with longer WIT in period 3 (odds ratio: 3.900; 95% confidence interval: 1.004-15.276; p = 0.044), but the tumor diameter and the total RENAL score were not. CONCLUSIONS: A large tumor in the central lesion indicated by the RENAL L-component score was associated with increased WIT in RALPN.
-
Takayama K.
IJU Case Reports ( IJU Case Reports ) 5 ( 6 ) 517 - 520 2022年11月
Introduction: Complete remission of cerebral metastasis is a rare consequence of tyrosine kinase inhibitor monotherapy in patients with metastatic renal cell carcinoma. Case presentation: A 68-year-old woman, who presented with dyspnea, was diagnosed with left renal cell carcinoma with multiple brain and pleural metastases. Although nivolumab and ipilimumab combination treatment was initiated, it was discontinued because of an immune-related adverse event. Two months after treatment cessation, brain metastases progressed regardless of shrinkage of primary renal tumor and pleural metastases. Therefore, axitinib was started as a second-line treatment, which resulted in the complete disappearance of the brain metastases along with the stable disease of the other tumor lesions. Conclusion: This is the first report of complete remission of brain metastases in renal cell carcinoma treated by axitinib.
-
Kimura H.
British Journal of Cancer ( British Journal of Cancer ) 127 ( 9 ) 1680 - 1690 2022年11月
BACKGROUND: The prognostic significance of germline variants in homologous recombination repair genes in advanced prostate cancer (PCa), especially with regard to hormonal therapy, remains controversial. METHODS: Germline DNA from 549 Japanese men with metastatic and/or castration-resistant PCa was sequenced for 27 cancer-predisposing genes. The associations between pathogenic variants and clinical outcomes were examined. Further, for comparison, DNA from prostate biopsy tissue samples from 80 independent patients with metastatic PCa were analysed. RESULTS: Forty-four (8%) patients carried germline pathogenic variants in one of the analysed genes. BRCA2 was most frequently altered (n = 19), followed by HOXB13 (n = 9), PALB2 (n = 5) and ATM (n = 5). Further, the BRCA1, BRCA2, PALB2 and ATM variants showed significant association with a short time to castration resistance and overall survival (hazard ratio = 1.99 and 2.36; 95% CI, 1.15-3.44 and 1.23-4.51, respectively), independent of other clinical variables. Based on log-rank tests, the time to castration resistance was also significantly short in patients with BRCA1, BRCA2, PALB2 or ATM somatic mutations and TP53 mutations. CONCLUSIONS: Germline variants in BRCA1, BRCA2, PALB2 or ATM are independent prognostic factors of the short duration of response to hormonal therapy in advanced PCa.